Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526022 | 1.00 | CYP1A2 (0.37) | CYP1A2RENMETAP1CTSKMETAP2 | |
| SCHEMBL15858469 | 1.00 | CYP1A2 (0.37) | CYP1A2RENMETAP1CTSKMETAP2 | |
| SCHEMBL12204090 | 1.00 | CYP1A2 (0.37) | CYP1A2RENMETAP1CTSKMETAP2 | |
| SCHEMBL25822676 | 1.00 | CYP1A2 (0.37) | CYP1A2RENMETAP1CTSKMETAP2 | |
| SCHEMBL3901737 | 0.97 | — | — | |
| SCHEMBL12262022 | 0.97 | — | — | |
| SCHEMBL525855 | 0.97 | — | — | |
| SCHEMBL21765542 | 0.92 | — | — | |
| SCHEMBL525786 | 0.92 | — | — | |
| SCHEMBL14615992 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271612-A | Polyimide precursor solution with high solid content and low viscosity, and preparation method and application thereof | 浙江奥首材料科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-03-30 | — | — | US | disclosed |
| US-20220219002-A1 | COLLECTION OF CLINICAL DATA FOR GRAPHICAL REPRESENTATION AND ANALYSIS | BOSTON SCIENT NEUROMODULATION CORP (US) | 2022-07-14 | — | — | US | disclosed |
| US-11324959-B2 | Collection of clinical data for graphical representation and analysis | BOSTON SCIENTIFIC NEUROMODULATION CORPORATION (US) | 2022-05-10 | — | — | US | disclosed |
| US-11261201-B2 | TRNA synthetase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-01 | — | — | US | disclosed |
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | PURDUE PHARMA L.P. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-02-25 | — | — | US | disclosed |
| EP-3733644-A1 | ORGANIC AMINE COLLECTION METHOD | Asahi Kasei Kabushiki Kaisha (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20200222704-A1 | COLLECTION OF CLINICAL DATA FOR GRAPHICAL REPRESENTATION AND ANALYSIS | BOSTON SCIENT NEUROMODULATION CORP (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200223847-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-07-16 | — | — | US | disclosed |
| US-4816549-A | FATTYAMINE CHAIN STOPPER | UNION CAMP CORPORATION (US) | 1989-03-28 | — | — | US | disclosed |
| EP-0132542-B1 | HYDROHALOGENATION OF CONJUGATED DIENES IN THE PRESENCE OF ORGANIC AMINES | Union Camp Corporation (US) | 1986-10-08 | — | — | EP | disclosed |
| EP-0132542-A1 | Hydrohalogenation of conjugated dienes in the presence of organic amines | Union Camp Corporation (US) | 1985-02-13 | — | — | EP | disclosed |
| US-4390712-A | Aqueous solution of cationic organosilicon compounds and process for the production of the solutions | DEGUSSA AG (DE) | 1983-06-28 | — | — | US | disclosed |
| US-4277498-A | Amides | BURROUGHS WELLCOME CO. (US) | 1981-07-07 | — | — | US | disclosed |
| US-4251542-A | Imino compounds | CIBA-GEIGY CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
| US-4130652-A | 2-(Iminoethylidene)-pyrrolidines and tautomeric 2-(aminoethenyl)-1-pyrrolines | CIBA-GEIGY CORPORATION (US) | 1978-12-19 | — | — | US | disclosed |
| US-RE29324-E | N-Substituted aspartyl peptide amides | G. D. SEARLE & CO. (US) | 1977-07-26 | — | — | US | disclosed |
| US-4011260-A | 3-AMINO-N-SUBSTITUTED SUCCINAMIC ACIDS AND INTERMEDIATES THERETO | G. D. SEARLE & CO. (US) | 1977-03-08 | — | — | US | disclosed |
| US-3965220-A | AMINE CATALYST | MONSANTO COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | CYP1A2 3568/4885REN 2951/4885METAP1 619/4885 |
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | QDPR, P2RX4, P2RX5 | CYP1A2 666/4885REN 976/4885METAP1 3819/4885 |
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | CYP1A2 3568/4885REN 2951/4885METAP1 619/4885 |
| US-20200223847-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, OPRK1, QDPR | CYP1A2 979/4885REN 2194/4885METAP1 3691/4885 |
| US-11261201-B2 | TRNA synthetase inhibitors | TRMT1, AARS1, GARS1 | CYP1A2 3568/4885REN 2951/4885METAP1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.